ID
45160
Descripción
Principal Investigator: Mark A. Rubin, MD, Weill Cornell Medical College, New York, NY, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000311 We have developed FusionSeq to identify fusion transcripts from paired-end RNA-sequencing. FusionSeq includes filters to remove spurious candidate fusions with artifacts such as misalignments or random pairing of transcript fragments and it ranks candidates according to several statistics. It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including 8 cancers with and without known rearrangements.
Link
Palabras clave
Versiones (2)
- 28/8/22 28/8/22 - Simon Heim
- 12/10/22 12/10/22 - Adrian Schulz
Titular de derechos de autor
Mark A. Rubin, MD, Weill Cornell Medical College, New York, NY, USA
Subido en
12 de octubre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000311 FusionSeq: Finding Fusions with Paired-End RNA-Seq
Sample ID and sample source of participants with prostate cancer.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, consent group, and affection status of participants with prostate cancer.
- Sample ID and sample source of participants with prostate cancer.
- Subject age, height, and family history of participants with prostate cancer.
- Sample ID, sample and tumor characteristics including tumor stage, grade, location, and sample type of participants with prostate cancer.
Similar models
Sample ID and sample source of participants with prostate cancer.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, consent group, and affection status of participants with prostate cancer.
- Sample ID and sample source of participants with prostate cancer.
- Subject age, height, and family history of participants with prostate cancer.
- Sample ID, sample and tumor characteristics including tumor stage, grade, location, and sample type of participants with prostate cancer.
C2348585 (UMLS CUI [1,2])
C2348585 (UMLS CUI [1,2])
C2348585 (UMLS CUI [1,2])